1 **Improvement in Inner Retinal Function in Glaucoma with Nicotinamide (Vitamin** 2 **B₃) Supplementation: A Crossover Randomised Clinical Trial**

3 **Authors:** Flora Hui, PhD^{1,†}, Jessica Tang, MBBS(Hons) PhD^{1,2}, Pete A Williams, PhD³, Myra
4 B McGuinness, PhD¹, Xavier Hadoux, PhD¹, Robert J Casson, DPhil FRANZCO⁴, Michael
5 Coote, MBBS FRANZCO^{1,2}, Ian A Trounce PhD^{1,2}, Keith R. Martin, DM FRCOphth^{1,2,5}, Peter
6 van Wijngaarden, PhD FRANZCO^{1,2}, Jonathan G Crowston, PhD FRANZCO^{1,2,6,7}

7
8 ¹ Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne,
9 Australia

10 ² Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Australia

11 ³ Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital,
12 Karolinska Institutet, Stockholm, Sweden

13 ⁴ Ophthalmic Research Laboratories, Discipline of Ophthalmology and Visual Sciences,
14 University of Adelaide, Adelaide, Australia

15 ⁵ Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom

16 ⁶ Centre for Vision Research, Duke-NUS Medical School, Singapore

17 ⁷ Singapore Eye Research Institute, Singapore National Eye Centre, Singapore

18 [†] Corresponding author

19 **Financial support:** Ophthalmic Research Institute of Australia (FH); Jack Brockhoff
20 Foundation, Marian and E.H. Flack Trust – JBF Grant number 4354 – 2017 (FH); Jean Miller
21 Foundation (JGC); Connie and Craig Kimberley Fund (IAT, JGC). Board of Research Faculty
22 Funded Career position (Karolinska Institutet) (PAW). The Centre for Eye Research Australia
23 receives operational infrastructure support from the Victorian Government. The funding
24 organisations had no role in the design or conduct of this research.

25 **Running head:** Nicotinamide improves retinal function in glaucoma

26 **Word count:** 3691

27 **Abbreviations and Acronyms:** ATP – adenosine triphosphate, CI – confidence interval,
 28 COR – coefficient of repeatability, ERG – electroretinogram, IOL – intraocular lens, IOP –
 29 intraocular pressure, IQR – interquartile range, MD – mean deviation, MLS – mean light
 30 sensitivity, NAD⁺ – nicotinamide adenine dinucleotide, NAM – nicotinamide, PL – placebo,
 31 POAG – primary open-angle glaucoma, PhNR – photopic negative response, PSD – pattern
 32 standard deviation, Q1 – lower quartile, Q3 – upper quartile, RGC – retinal ganglion cell,
 33 RNFL – retinal nerve fibre layer, VF – visual field, Vmax – saturating amplitude

34 **Corresponding author:**

35 Dr Flora Hui
 36 Centre for Eye Research Australia
 37 Level 7, Peter Howson Wing, 32 Gisborne Street
 38 East Melbourne, VIC 3002, Australia
 39 f.hui@unimelb.edu.au

40 **Conflict of interest:** No conflicting relationship exists for any author.

41 **Data sharing statement:** Clinical data was collected at the Centre for Eye Research Australia
 42 in collaboration with the Royal Victorian Eye and Ear Hospital and Melbourne Eye Specialists.
 43 These data are not publicly available. Source data of graphs may be available as source files if
 44 requested. A description of the code used to analyse the electroretinogram data is described in
 45 the Methods section, and we have also published this previously (Tang et al, 2018).

46 Abstract

47 **Importance:** Retinal ganglion cells endure significant metabolic stress in glaucoma but
48 maintain capacity to recover function. Nicotinamide, a precursor of NAD^+ , is low in serum of
49 glaucoma patients and its supplementation provides robust protection of retinal ganglion cells in
50 preclinical models. However, the potential of nicotinamide in human glaucoma is unknown.

51 **Background:** To determine whether nicotinamide supplementation alongside conventional
52 IOP-lowering therapy improves retinal ganglion cell function in glaucoma.

53 **Design:** Crossover, double-masked, randomised clinical trial. Participants recruited from two
54 tertiary care centres.

55 **Participants:** Fifty-seven participants, diagnosed and treated for primary glaucoma, enrolled.

56 **Methods:** Participants received oral placebo or nicotinamide and reviewed six-weekly.
57 Participants commenced 6-weeks of 1.5 grams/day then 6 weeks of 3.0 grams/day followed by
58 crossover without washout. Visual function measured using electroretinography and perimetry.

59 **Main outcome measures:** Change in inner retinal function, determined by photopic negative
60 response (PhNR) parameters: saturated PhNR amplitude (V_{max}), ratio of PhNR/b-wave
61 amplitude (V_{max} ratio).

62 **Results:** PhNR V_{max} improved beyond 95% coefficient of repeatability (COR) in 23% of
63 participants following nicotinamide versus 9% on placebo. Overall, V_{max} improved by 14.8%
64 [95% CI: 2.8%, 26.9%], ($p=0.02$) on nicotinamide and 5.2% [-4.2%, 14.6%], ($p=0.27$) on
65 placebo. V_{max} ratio improved by 12.6% [5.0%, 20.2%], ($p=0.002$) following nicotinamide,
66 3.6% [-3.4%, 10.5%], ($p=0.30$) on placebo. A trend for improved visual field mean deviation
67 was observed with 27% improving $\geq 1\text{dB}$ on nicotinamide and fewer deteriorating (4%)
68 compared to placebo ($p=0.02$).

69 **Conclusions:** Nicotinamide supplementation can improve inner retinal function in glaucoma.
70 Further studies underway to elucidate the effects of long-term nicotinamide supplementation.

71 **Trial Registration:** ANZCTR trial ID: ACTRN12617000809336

72 <https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373001>

73 **Keywords:** nicotinamide, glaucoma, electroretinography, neuroprotection, vitamin B3

75 **Introduction**

76 Glaucoma remains the leading cause of irreversible blindness worldwide.¹ The disease has a
 77 complex aetiology and range of risk factors but is characterised by gradual dysfunction and loss
 78 of retinal ganglion cells (RGCs) and their axons which make up the optic nerve.² This slow,
 79 progressive loss of visual function hinders the translation of potential neuroprotective
 80 therapeutics from bench-to-bedside due to the extended time needed to determine treatment-
 81 induced changes in glaucoma progression rates. Age,¹ genetics,³ and elevated intraocular
 82 pressure (IOP)⁴ are all major risk factors for glaucoma yet clinically available treatment
 83 strategies target only IOP-lowering, and do not directly target the neurodegenerative events at
 84 the level of the retina and optic nerve. As many patients are refractory to IOP lowering or
 85 progress to blindness despite low IOP, neuroprotective strategies that directly target RGC health
 86 and decrease vulnerability to glaucoma-related cellular stressors are urgently needed.
 87 Accumulating evidence points to the potential for visual recovery in clinical glaucoma in
 88 response to IOP-lowering.⁵⁻⁷ Recovery of visual function can occur soon after restoration of IOP
 89 and, as such, objective measures of visual function have potential as surrogate biomarkers of
 90 improved RGC health.

91 The photopic negative (PhNR) and positive scotopic threshold responses are parameters of the
 92 electroretinogram (ERG) that are largely generated by RGCs in the inner retina.⁸⁻¹⁰ RGC
 93 function has been shown to recover after acute and chronic IOP insults even after prolonged
 94 periods of functional loss.¹¹⁻¹³ Capacity for recovery is reduced with advancing age¹⁴ and can be
 95 modified by interventions such as exercise and diet restriction.^{15,16} Using ERG protocols similar
 96 to those validated in rodent studies, we have demonstrated improvements in RGC function in
 97 humans, as early as 3-months following IOP-lowering in glaucoma.⁵ Recent work has
 98 significantly improved repeatability of the PhNR measurement, enabling detection of subtle
 99 changes in inner retinal function.^{17,18}

Several lines of evidence implicate oxidative stress and mitochondrial dysfunction in ageing¹⁹ and RGC loss in glaucoma.^{20,21} Nicotinamide adenine dinucleotide (NAD^+) is an essential cofactor for ATP generation in mitochondria, and for NAD-consuming enzymes including sirtuins (Figure 1), with important roles in ageing, cell senescence, and stress resistance.²²

Figure 1. The role of nicotinamide adenine dinucleotide (NAD^+ , blue) in adenosine triphosphate (ATP) production. The pathways through which NAD^+ is created and salvaged, the major enzymes involved and the process in which NAD^+ supplements, nicotinamide (green) and nicotinamide riboside, may replete NAD^+ levels. Complex I (yellow) within the electron transport chain, where nicotinamide adenine dinucleotide + hydrogen (NADH) is oxidized to NAD^+ and site of potential mitochondrial dysfunction in glaucoma. NAAD – nicotinic acid adenine dinucleotide.

NAD^+ is a potent mediator of axon neuroprotection and recently, the therapeutic potential of modulating NAD^+ metabolism has gained widespread attention in its role in ageing and neurodegenerative disease.²³⁻²⁵ A number of studies are currently investigating the effect of

116 NAD⁺ repletion in a range of neurodegenerative disorders including Alzheimer's disease
 117 (NCT00580931, NCT03061474) and peripheral small fibre neuropathy (NCT03912220).
 118 Recent work has indicated that patients with primary open-angle glaucoma (POAG) have
 119 reduced serum levels of nicotinamide (NAM, the amide of vitamin B₃ and precursor for NAD⁺),
 120 indicating that systemic NAD⁺ levels may be associated with susceptibility to glaucoma.²⁶ In
 121 support of this hypothesis, Williams et al²⁷ demonstrated that increasing retinal NAD⁺ levels
 122 with dietary NAM or overexpression of a NAD-producing enzyme (*Nmnat1*) provided robust
 123 long-term neuroprotection of RGCs, reversed age-related transcriptomic changes, and preserved
 124 RGC function in an inherited mouse model of glaucoma (DBA/2J). These findings support the
 125 hypothesis that NAM supplementation has therapeutic potential. In addition, NAM has been
 126 safely used in a number of clinical studies with minimal adverse effects^{28,29} and, as such, NAM
 127 supplementation may be readily translated into clinical care and complement current therapies.
 128 We therefore sought to determine whether functional improvements observed with NAM
 129 supplementation in mice could be recapitulated in humans with glaucoma in an interventional
 130 study using the ERG PhNR and visual fields (VF) as main outcome measures. This study sought
 131 to determine whether NAM, a potential neuroprotectant that targets bioenergetic insufficiency
 132 in glaucoma, could lead to a detectable improvement in inner retinal function.

133

134 **Methods**

135 **Study Design, Participants**

136 This study was a prospective, double-masked, randomized, crossover clinical trial conducted in
 137 Melbourne, Australia between October 2017 and January 2019. The study schedule is presented
 138 in Figure 2.

139

140 **Figure 2. Study schedule.** BMI – body mass index, ERG – electroretinogram, IOP – intraocular
141 pressure, MAP – mean arterial pressure, NAM – nicotinamide, OCT – optical coherence
142 tomography, VF – visual fields.

143

144 All procedures were approved by the Human Research Ethics Committee at the Royal Victorian
145 Eye and Ear Hospital (17/1339H). Written informed consent was obtained from all participants
146 prior to all procedures. Participants were recruited from public outpatient and private
147 ophthalmology clinics (Royal Victorian Eye and Ear Hospital, Melbourne Eye Specialists). All
148 testing was performed at the Centre for Eye Research Australia. Inclusion criteria included adult
149 participants diagnosed and treated for glaucoma by a sub-specialist ophthalmologist, and with
150 visual acuity of at least 6/18. Participants were required to have performed a reliable VF (SITA-
151 Standard 24-2, HFA II-750i, Carl Zeiss Meditec AG, Germany) in the last 6 months, with <33%
152 fixation losses, false positives and false negatives.³⁰ Eligible participants had reproducible VF

153 defects of at least 3 neighbouring points with a sensitivity below the age-matched normal (total
154 deviation) with a probability of <2%.³¹ Where both eyes were eligible, the eye with the better
155 VF was chosen.

156 Exclusion criteria included pregnancy/breastfeeding, allergy to NAM/niacin, history of cancer
157 in the last 5 years (except treated basal or squamous cell carcinoma), liver disease or stomach
158 ulcers. Ophthalmic exclusion criteria included intraocular surgery in the past 6 months
159 (uncomplicated cataract surgery within the last 3 months) and diseases known to affect retinal
160 function (e.g. age-related macular degeneration, diabetic retinopathy).

161

162 As this study involved high-dose NAM, an accelerated dosing protocol was used to facilitate
163 tolerability. Participants were randomised 1:1 with randomly selected block sizes of 4, 6 and 8
164 using a computer-generated list to the intervention in either the first or second study period. The
165 intervention consisted of a 6-week course of NAM (Insolar®, 0.5 g NAM tablet, Blackmores,
166 NSW, Australia) of 1.5 g/day followed by 6 weeks of 3.0 g/day, (1.5 g twice a day, morning and
167 evening). Placebo (PL) tablets were manufactured to match the appearance and texture of the
168 active treatment (Pharmaceutical Packaging Professionals, Melbourne, Australia). Placebo and
169 active treatment bottles were identical and coded with unique numerical identifiers. Participants
170 randomised to receive placebo also doubled the number of tablets after 6 weeks to ensure they
171 remained masked. Treatment was dispensed by the study coordinator at the conclusion of Visit
172 1 following capture of baseline measurements. Participants, treating physicians, certified
173 assessors and biostatisticians were masked to treatment allocation. The NAM dosage of 3.0
174 g/day was based on that used in preclinical studies,²⁷ other published²⁸ and ongoing human trials
175 of NAM treatment (NCT00580931, NCT03061474).

176

177 After 12 weeks, participants crossed over without washout, such that those previously on
178 placebo treatment commenced NAM and vice versa. A washout was deemed unnecessary as
179 any effect from NAM was assumed to be undetectable by the time of the next review visit.

180 Treatment was taken in conjunction with any glaucoma therapies participants were already
181 using. To monitor treatment adherence, participants were asked to bring remaining tablets to
182 each study visit and tablets were manually counted by the study coordinator. A minimum
183 adherence rate of 70% was acceptable, equating to no more than two missed doses a week.

184 **Clinical Testing**

185 All participants were seen at baseline (Visit 1), and reviewed 6-weekly (± 2 weeks). At each visit,
186 participants underwent a standard clinical examination, including measurement of visual acuity
187 (EDTRS letters), IOP (Icare® PRO, Icare Finland Oy, Finland), blood pressure (HEM-7322,
188 Omron Healthcare, Japan) and slit lamp examination. Standard automated perimetry was
189 performed on the study eye (SITA-Standard 24-2, HFA II-750i, Carl Zeiss Meditec AG,
190 Germany) and pupils were dilated (to ≥ 6 mm) using 0.5% tropicamide and 2.5% phenylephrine
191 (Bausch and Lomb, NSW, Australia). Participants were light-adapted for at least 10 minutes
192 before photopic ERG recording. ERGs were recorded with custom-made DTL-like electrodes
193 using silver impregnated fibre (22/1 dtex, Shieldex trading, NY, USA) and a handheld device
194 (RETeval™, LKC Technologies, MD, USA). Reference and ground gold-cup electrodes (Grass
195 Technologies, Astro-Med Inc., RI, USA) were placed at the temple and forehead respectively.
196 For optimal PhNR recording, a series of red flashes (621 nm, 16 luminous energies between
197 0.07-12.56 cd.s/m², 50 sweeps, 2 Hz flash interval,³² Figure 3A) on a blue background (470 nm,
198 10 photopic cd/m²) was used. Stimuli were calibrated using the ILT-1700 radiometer
199 (International Light Technologies, MA, USA) with a photopic filter. Participants underwent
200 optical coherence tomography (OCT) to measure retinal nerve fibre layer (RNFL) thickness
201 (Spectralis SD-OCT, Heidelberg Engineering, Dossenheim, Germany).

202 **Study Objectives**

203 The primary objective was to evaluate the change in retinal function as measured by ERG and
204 VF parameters after 12 weeks of high-dose NAM supplementation compared to placebo.

Specifically, changes from baseline and placebo in PhNR saturating amplitude (PhNR Vmax), PhNR/b-wave ratio (Vmax ratio) and VF indices (mean deviation, MD; pattern standard deviation, PSD; mean light sensitivity, MLS) were analysed. Secondary objectives included changes to RNFL thickness, IOP and mean arterial pressure (MAP).

Data analysis

ERG waveforms were processed as described previously.¹⁸ In brief, custom-written Matlab® scripts (R2018b, Mathworks, MA, USA) were used to process raw ERG traces. ERG waveforms were processed by an assessor masked to participant characteristics, treatment group and timepoint of measurement. First, a bandpass filter (0.3 – 300 Hz) was applied. The raw data was detrended with a 3rd order polynomial, which was shown to provide the most robust PhNR signal.¹⁸ Amplitudes and implicit times of the a-wave, b-wave (from a-wave trough to b-wave peak) and PhNR (minimum from baseline to trough) were extracted.

Amplitudes of the b-wave and PhNR (Figure 3B) across the luminance series were modelled using a saturating hyperbolic function,³³ defined as $V(I) = V_{max} * I^n / (I^n + K^n)$, where V (μV) is the amplitude as a function of luminous exposure (I), Vmax the saturating amplitude (μV), K the semi-saturation constant (1/K is the sensitivity) and n the slope (Figure 3C-D). For the PhNR, n was fixed at 1.2 (consistent with our pilot data, and similar to others).^{34,35} Further, the PhNR Vmax was analysed as a ratio to the b-wave Vmax (Vmax ratio) to account for any changes to the b-wave between sessions.

225

226 **Figure 3. Electretinogram (ERG) analysis method.** A. Representative ERG luminance-
 227 response series showing every second luminance step, B. ERG parameters of interest, C.
 228 Representative b-wave luminance-response function data (circles) and model derived from a
 229 saturating hyperbolic function (line), D. Representative PhNR luminance-response function
 230 (circles), corresponding model (line) and model parameters: V_{max} (saturating amplitude), n
 231 (slope) and K (semi-saturation constant).

232

233 In addition to VF MD and PSD, the mean light sensitivity (MLS) was calculated as the average
 234 of all perimetric sensitivity values on a 24-2 visual field (excluding one point above and below
 235 the blind spot). Visual field parameters are conventionally expressed in logarithmic decibel (dB)
 236 scale, however, these were converted to a linear scale (1/lambert) where, $dB = 10 \cdot$
 237 $\log(1/lambert)$ before correlating with other measures.^{36,37} The proportion of participants with

238 a ≥ 1 dB change in MD and PSD in NAM and placebo groups were determined and compared
239 using Fisher's exact test.

240 **Statistical Analysis**

241 Data from one eye per participant were included in the analyses. Prior to study commencement,
242 sample size was calculated based on results of previous work investigating short-term changes
243 in PhNR Vmax ratio following IOP reduction (under review). Assuming an attrition rate of 20%,
244 it was estimated that 48 eyes were required to achieve 80% power to detect a difference
245 between treatment periods with an effect size of 0.56 for Vmax ratio and two-sided hypothesis
246 test with an α level of 0.05.

247 The primary analysis set included participants who attended all study visits. Statistical analyses
248 were conducted with the statistician masked to intervention using Stata (SE version 15.1, Texas,
249 US). Treatment adherence was compared between randomisation groups using the Wilcoxon
250 rank-sum test. As a washout period was not utilised, a pre-test for carryover effects was
251 conducted for each parameter.³⁸ The within-participant sum of values for each parameter was
252 calculated by adding change from baseline values observed under placebo to those under NAM
253 and compared between randomisation groups using two-sample t-test. To test for a period effect,
254 the within participant difference (NAM-PL) was compared between treatment groups using
255 linear regression, adjusting for baseline values of each parameter. The treatment effect for each
256 parameter was assessed following the high-dose period by examining the magnitude and
257 direction of the within-participant difference via linear regression, with adjustment for mean-
258 centred baseline values. Values were analysed in original units of measurement. If a statistically
259 significant treatment effect was found at 12-weeks for any endpoint, then the 6-week timepoint
260 was also assessed. Changes in PhNR parameters were also compared to the 95% coefficient of
261 repeatability (COR) established from our previous work.¹⁷

262

263 Missing ERG values were associated with fatigue or persistent muscle twitch during recordings
264 that could not be ameliorated with post-hoc signal processing. Values were multiply imputed
265 (25 imputed datasets) using fully conditional specification (chained equations) with a univariate
266 linear regression imputation model to reduce bias and maintain statistical power. In addition to
267 the imputation variables, imputation models included demographics, clinical data and study
268 group. As a sensitivity analysis, complete-case analyses were performed using the per-protocol
269 set ($n = 43$) which only included participants who had non-missing data. Results are shown as
270 mean and [95% confidence interval], unless stated otherwise.

271

272 **Results**

273 **Participants**

274 Among 94 participants assessed after medical record screening, 57 were randomised into the
275 study, of which 49 (86%, 65.5 ± 10.0 years, 39% female) completed the study. The participant
276 flow chart is presented in Figure 2 and baseline characteristics of the participants included in the
277 primary analysis in Table 1.

278

Figure 4. CONSORT diagram. Participants were randomised to receive placebo first or nicotinamide first. Primary analysis set defined as participants who received both interventions and attended all visits. Per-protocol set defined as a subset of the primary analysis set, excluding any participants with missing data on outcome variables (n = 6). Participants lost to follow-up (n = 4), participants discontinuing intervention (n = 4). AE – adverse event, SE – side effect.

295 **Table 1. Baseline characteristics for participants in the primary analysis by treatment group**
 296 **(n = 49).**

	Placebo first (n = 23)	Nicotinamide first (n = 26)
	n (%)	n (%)
Sex		
Female	10 (43%)	8 (31%)
Male	13 (57%)	18 (69%)
Eye tested		
Left	11 (48%)	16 (62%)
Right	12 (52%)	10 (38%)
Presence of IOL		
No	12 (52%)	14 (54%)
Yes	11 (48%)	12 (46%)
Glaucoma diagnosis		
POAG	14 (61%)	16 (62%)
CACG	5 (22%)	3 (12%)
NTG	2 (9%)	5 (19%)
PXF	1 (4%)	2 (8%)
PDG	1 (4%)	0 (0%)
	Mean (SD)	Mean (SD)
Age (years)	67.01 (2.05)	65.30 (2.14)
Visual acuity (logMAR)	0.01 (0.14)	-0.01 (0.11)
Intraocular pressure (mmHg)	13.6 (2.7)	14.5 (3.3)
ERG b-wave fitting parameter: n [†]	1.32 (0.16)	1.29 (0.17)
ERG b-wave Vmax (μV) [†]	108.87 (27.48)	99.00 (29.75)
ERG b-wave fitting parameter: 1/K [†]	1.22 (0.30)	1.12 (0.41)
	Median (Q1, Q3)	Median (Q1, Q3)
Mean arterial pressure (mmHg) [†]	92.17 (85.00, 96.00)	95.67 (88.17, 98.67)
ERG PhNR fitting parameter: 1/K [†]	2.40 (1.24, 3.64)	1.64 (1.27, 2.68)
ERG PhNR Vmax (μV) [†]	15.30 (11.10, 20.58)	11.39 (9.31, 13.49)
PhNR Vmax/b-wave Vmax ratio [†]	0.14 (0.11, 0.20)	0.12 (0.10, 0.14)
Visual field MD (24-2) dB	-5.46 (-7.20, -1.10)	-4.51 (-8.37, -1.84)
Visual field PSD (24-2) dB	6.77 (2.37, 9.85)	5.89 (3.06, 9.28)

[†]Missing values in Groups 1 and 2, respectively: ERG b-wave fitting parameter: n, maximum amplitude and fitting parameter: 1/K (n=2 and 3), mean arterial pressure (n=5 and 2), ERG PhNR (μV), fitting parameter: 1/K (n=3 and 3), PhNR Vmax/b-wave Vmax ratio (n=3 and 3).
 ERG – electroretinogram, IOL – intraocular lens, MD – mean deviation, NTG – normal tension glaucoma, POAG – primary open-angle glaucoma, PDG – pigment dispersion glaucoma, PhNR – photopic negative response, PSD – pattern standard deviation, PXFG – pseudoexfoliative glaucoma, Q1 – lower quartile, Q3 – upper quartile, SD – standard deviation, Vmax – saturated amplitude.

297
 298 Majority of participants had primary open angle glaucoma (POAG, 63%), then chronic angle
 299 closure glaucoma (16%) and normal tension glaucoma (12%). Adherence rates were high for
 300 both NAM and placebo, with >94% adherence to NAM, demonstrating the high tolerability of

both low and high-dose NAM supplementation (Table 2). Only two participants (3%) were non-adherent on NAM and removed from analysis after failing to attend all study visits.

Table 2. Distribution of days from baseline to follow-up for participants included in the primary analysis and adherence rates (%) at each visit. Treatment group 1 received placebo (PL) first, Treatment group received nicotinamide (NAM) first. P-values derived from Wilcoxon rank-sum test to test for differences in adherence between groups, $n = 49$ in total.

Visit no.	Treatment group	Days from baseline			Adherence (%)		
		Target	Mean	SD	Median	[Q1, Q3]	p-value
2 (6 weeks)	Treatment group 1, PL	42	42.5	6.2	97.6	[88.1, 100.0]	0.80
	Treatment group 2, NAM	42	42.2	5.0	97.6	[90.5, 100.0]	
3 (12 weeks)	Treatment group 1, PL	84	85.6	5.0	95.2	[89.7, 99.2]	0.70
	Treatment group 2, NAM	84	85.4	5.3	94.4	[91.5, 96.0]	
4 (18 weeks)	Treatment group 1, NAM	126	126.8	5.7	100.0	[97.6, 100.0]	0.89
	Treatment group 2, PL	126	130.4	8.7	100.0	[92.9, 100.0]	
5 (24 weeks)	Treatment group 1, NAM	168	171.0	6.3	96.6	[93.7, 98.7]	0.46
	Treatment group 2, PL	168	169.9	10.5	94.0	[90.5, 99.2]	

NAM – nicotinamide, PL – placebo, Q1 – lower quartile, Q3 – upper quartile, SD – standard deviation

Improvement in Retinal Ganglion Cell Function Following Nicotinamide Treatment

At the 12-week visit, significant improvements in inner retinal function were found in the high-dose NAM arm, with 23% (PhNR Vmax) and 21% (Vmax ratio) of the group improving beyond the respective 95% COR for each measure. Fewer participants on placebo demonstrated improvement (PhNR Vmax: 9%; Vmax ratio: 14%). Some participants deteriorated beyond the COR (9% on placebo, 7% on NAM had a reduced Vmax; 5% on placebo, 2% on NAM had a reduced Vmax ratio). A significant difference in overall treatment effect was found for both Vmax ratio (NAM-PL: 0.01 [0.002, 0.025], $p = 0.02$) and PhNR Vmax (NAM-PL: 1.35 μ V [0.159, 2.551], $p = 0.03$, Figure 5A-B, Supplementary Table 1). PhNR sensitivity (1/K) did not change with treatment ($p = 0.41$). Overall there was 12.6% [5.0, 20.2] ($p = 0.002$, Figure 5C) improvement in Vmax ratio between baseline and 12-weeks following NAM compared to 3.6% [-3.4, 10.5] ($p = 0.30$) with placebo (between group difference 9.0%, $p = 0.03$). PhNR Vmax improved by 14.8% [2.8, 26.9] ($p = 0.02$, Figure 5D) on NAM, compared to 5.2% [-4.2, 14.6] ($p = 0.27$) on placebo (between group difference 9.6%, $p = 0.04$). There was no evidence of carryover or period effects (Supplementary Tables 1 & 2) and inference was unchanged in the sensitivity analyses of the complete-case set after omitting participants with missing ERG data (Supplementary Table 2). In addition, no significant changes were noted at 6-weeks with low-dose NAM or placebo. There was no evidence of a correlation between the PhNR treatment effect and age, sex, or BMI (Supplementary Figure 1).

In addition, there was no evidence of a treatment effect on ERG measures of outer retinal function including the a-wave (photoreceptor function, Figure 5E-F) and b-wave (bipolar cell function, Figure 5G-H) amplitudes or implicit times between NAM and placebo. No differences were found for any b-wave fitting parameters between NAM and placebo groups following the low or high-dose periods (Supplementary Table 1).

Figure 5. Significant improvement in the photopic negative response (inner retinal function) at 12-weeks post nicotinamide intervention. A. Difference in Vmax ratio between nicotinamide (NAM) and placebo (PL) at 6-weeks (NAM₆ – PL₆, circles) and 12-weeks (NAM₁₂ – PL₁₂, diamonds) showing significant increase at NAM₁₂ ($p = 0.02$), B. PhNR Vmax (μV) showing a significant increase at

NAM_{12} ($p = 0.03$), C. Vmax ratio expressed as relative change from baseline (%) for nicotinamide (blue) and placebo (pink) at 6 and 12-weeks, with a significant change at NAM_{12} ($p = 0.002$, one sample t -test), D. PhNR Vmax (NAM_{12} , $p = 0.02$), E-F. Luminance-response series for the a-wave and b-wave. No significant difference in a-wave amplitude and implicit time (photoreceptor) following placebo and nicotinamide treatment after low dose (6-weeks, circles) or high dose periods (12-weeks, diamonds). G-H. No significant change in b-wave amplitudes and implicit times (bipolar cell) following treatment; mean $\pm$ 95% CI, $n = 43$. Base – baseline, NAM_6 – nicotinamide at 6-weeks, NAM_{12} – nicotinamide at 12-weeks, PL_6 – placebo at 6-weeks, PL_{12} – placebo at 12-weeks.

Perimetric Changes with Nicotinamide

There were no significant differences in global VF indices between treatment groups (Supplementary Table 1). After 12 weeks of NAM, average MD was no different to placebo (NAM-PL: 0.10 dB [-0.33, 0.53], $p = 0.63$, Figure 6A). Similarly, PSD reduced only slightly with NAM (NAM-PL: -0.25 dB [-0.63, 0.14], $p = 0.20$, Figure 6B). Changes in MD and PSD scores for each individual are shown in Figure 6A-B. A greater proportion of participants had an increase in MD by ≥ 1 dB from baseline following high-dose NAM compared to placebo (27% vs. 16%) and fewer patients taking high-dose NAM had a decrease by ≥ 1 dB compared to placebo (4% vs 12%, $p = 0.02$, Figure 6C). This was not evident for PSD, where a similar proportion of participants had an increase or decrease by ≥ 1 dB following NAM and PL ($p = 0.61$, Figure 6D). A moderate positive correlation was found between changes in PhNR Vmax and VF MD at 12 weeks (Figure 6E-F) for both placebo (Pearson's $r = 0.34$, [0.05, 0.57], $p = 0.02$) and NAM treatment (Pearson's $r = 0.50$, [0.24, 0.70], $p = 0.0006$). There was also evidence of a moderate positive correlation between PhNR Vmax and VF MLS (Figure 6G-H) with placebo (Pearson's $r = 0.37$, [0.09, 0.60], $p = 0.01$) and NAM (Pearson's $r = 0.54$, [0.28, 0.72], $p = 0.0002$).

Figure 6. Changes in visual field (VF) parameters after treatment. A. Time-series plots of the difference in VF mean deviation (MD, dB) between nicotinamide (NAM) and placebo (PL) groups at 6 and 12- weeks for each individual, B. Difference in VF pattern standard deviation (PSD, dB) between NAM and placebo groups at 6 and 12- weeks, C. Proportion of participants (%) who

demonstrated an improvement (green) or worsening (red) of VF MD by ≥ 1 dB compared to baseline for NAM and placebo groups (Fisher's exact test, $p = 0.02$), D. Proportion of participants (%) who demonstrated an improvement (green) or worsening (red) of VF PSD by ≥ 1 dB compared to baseline, E. Linear positive correlation between VF MD (1/lambert) and the photopic negative response saturated amplitude (PhNR Vmax, μV) after 12-weeks of placebo (Pearson's $r = 0.34$, $p = 0.02$). Dashed lines show where VF MD in dB units (0, -3 and -6 dB) are located, F. Correlation between VF MD (1/lambert) and PhNR Vmax after 12-weeks of NAM (Pearson's $r = 0.50$, $p = 0.0006$), G. Correlation between VF mean light sensitivity (MLS, 1/lambert) and PhNR Vmax after 12-weeks of placebo (Pearson's $r = 0.37$, $p = 0.01$), H. Correlation between VF MLS and PhNR Vmax after 12-weeks of NAM (Pearson's $r = 0.54$, $p = 0.0002$); $n = 49$. Base – baseline, NAM₆ – nicotinamide at 6-weeks, NAM₁₂ – nicotinamide at 12-weeks, PL₆ – placebo at 6-weeks, PL₁₂ – placebo at 12-weeks.

IOP and RNFL Thickness Unchanged

There was no evidence of a difference between placebo and NAM in IOP, MAP or VA (Supplementary Table 1). IOP was 13.8 ± 4.1 mmHg (mean $\pm$ SD) following NAM compared to 13.4 ± 2.4 mmHg following placebo (mean adjusted NAM-PL: 0.2 mmHg [-0.58, 1.003], $p = 0.59$). Overall, there was no change in RNFL thickness. At 12-weeks, the difference in RNFL thickness compared to baseline was, NAM: -0.3 ± 2.9 μm compared to placebo: 0.4 ± 2.4 μm (mean $\pm$ SD, $p = 0.11$).

Adverse effects

In this study, high-dose NAM was well tolerated, the most common side effects being mild gastrointestinal discomfort (constipation or soft stools; 10.5%), nausea (5.3%) and headaches (3.5%). In the placebo group, 12.3% of participants reported difficulty in tablet swallowing, and 7.0% reported gastrointestinal discomfort. One participant withdrew after experiencing tinnitus whilst on placebo treatment. All symptoms resolved after participants ceased treatment.

393

394 Discussion

395 We provide evidence that NAM can lead to an early improvement in inner retinal function in a
396 significant proportion of IOP-treated glaucoma patients after 12-weeks of supplementation. The
397 majority of individuals whose PhNR parameters improved beyond 95% COR also improved in VF
398 MD. Overall, NAM was well tolerated with an adherence rate of >94%. As systemic NAM levels
399 have been shown to be reduced in patients with POAG,²⁶ NAM supplementation may be a convenient,
400 safe, and cost-effective therapy in conjunction with existing IOP-lowering strategies. A longer-term
401 study is being planned to determine whether these functional improvements are sustained and
402 associated with delayed glaucoma progression.

403

404 There is growing evidence that impairments in visual function that occur in experimental and clinical
405 glaucoma may recover following IOP-lowering^{5,6,39-41} or in response to the provision of bioenergetic
406 substrates.^{7,42} A number of reports have shown short-term improvement in contrast sensitivity and VF
407 parameters in response to IOP-lowering,^{6,41,43} and some studies indicate that these improvements in
408 visual function are sustained for extended periods.⁴⁴ Gandolfi et al showed significant improvements
409 in contrast sensitivity 3-9 months after trabeculectomy, which persisted for three years.⁶ Caprioli and
410 colleagues also demonstrated improved sensitivity on a point-wise VF analysis with long-term
411 improvement in 44% of VF locations, five years after trabeculectomy.⁴⁴ Studies have also provided
412 evidence of ERG improvement following glaucoma treatment. Improvements in pattern
413 electroretinography (PERG) were seen 3-months post-trabeculectomy³⁹ and following oral
414 acetazolamide.⁴⁰ Niyadurupola et al demonstrated increased PhNR amplitude following a >25% IOP
415 reduction.⁵ There is less evidence supporting visual recovery by means other than IOP-lowering.
416 Casson and colleagues demonstrated that elevating vitreous glucose levels temporarily improved
417 contrast sensitivity in pseudophakic individuals with POAG, in response to elevations in vitreous
418 glucose levels.⁷ In the present study, oral supplementation with the metabolic substrate, NAM, was
419 associated with a 14.8% [2.8%, 26.9%] improvement in PhNR Vmax amplitude and 12.6% [5.0%,

20.2%] improvement in Vmax ratio. Importantly, these effects were independent of IOP. This raises the prospect that oral NAM supplementation may serve as an adjunct to IOP-lowering therapies.

NAD⁺ depletion is observed in many tissues with advancing age⁴⁵ and serum levels of NAM decline in aged POAG patients.²⁶ The mechanisms by which NAD⁺ may improve RGC function are not known but work in animal models suggest that maintenance of mitochondrial integrity and function is a key factor.^{25,27,46,47} High-dose NAM supplementation in DBA/2J glaucoma-model mice prevented RGC soma loss, RNFL thinning, age-related transcriptional and structural changes in mitochondria and preserved RGC function as measured with PERG.^{27,46} NAM was protective as a prophylactic and therapeutic intervention in a dose-dependent manner. A similar level of neuroprotection was observed with the overexpression of NAD⁺ biosynthetic enzyme, *Nmnat1* in RGCs.²⁷ A synergistic effect was found with gene therapy and NAM. Human clinical studies have not previously examined the effect of NAM supplementation on visual function in glaucoma.

NAM is the amide form of vitamin B₃ yet is erroneously referred to as vitamin B₃ in much of the scientific and medical literature. In these contexts, vitamin B₃ encapsulates multiple compounds including niacin/nicotinic acid, which have known ocular and systemic side effects at high doses.⁴⁸ However, NAM supplements are widely commercially available and are relatively safe. The most common adverse effects reported in prior clinical studies of high-dose NAM (1.5-6 g/day) were skin flushing and nausea (≤1.5%).²⁹ Longitudinal studies will reveal the tolerability of long-term high-dose NAM supplementation.

We enrolled participants already treated for glaucoma with well-controlled IOP. As IOP was unchanged by oral NAM treatment, the observed effect of NAM on inner retinal function is unlikely to be mediated through changes in IOP. Instead, our findings suggest metabolic rescue of RGCs as a putative mechanism of NAM action. We hypothesise that NAM supplementation may benefit eyes with elevated IOP, which is associated with increased RGC metabolic stress and dysfunction.^{2,12} The NAM dosage used in our study was derived empirically from preclinical work and clinical trials of the

supplement for other indications. Therefore, it is possible that this dose was sub-optimal and that a single dose is not ideal for all, as pharmacokinetics and pharmacodynamics will differ, for example due to age, sex, or weight.⁴⁹ However, we did not observe a correlation between treatment effect and baseline demographics. Although a washout period was not utilized, there was no evidence of carryover effects, potentially due to the short plasma half-life of NAM in humans (3.5 hours after a dose of 25 mg/kg).⁵⁰

For the first time, we have provided evidence that oral NAM supplementation leads to an early and measurable improvement in inner retinal function in glaucoma patients already taking IOP-lowering medication. A larger clinical trial of long-term NAM treatment is now warranted to explore whether these effects are sustained and predict a slowing in glaucoma progression.

Acknowledgements: Professor David Crabb for his advice on visual field analyses.

References

1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology* 2014; **121**: 2081-90.
2. Alqawlaq S, Flanagan JG, Sivak JM. All roads lead to glaucoma: Induced retinal injury cascades contribute to a common neurodegenerative outcome. *Exp Eye Res* 2019; **183**: 88-97.
3. Wiggs JL, Pasquale LR. Genetics of glaucoma. *Hum Mol Genet* 2017; **26**: R21-R7.
4. Bengtsson B, Leske MC, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. *Ophthalmology* 2007; **114**: 205-9.
5. Niyadurupola N, Luu CD, Nguyen DQ, Geddes K, Tan GX, Wong CC, Tran T, Coote MA, Crowston JG. Intraocular pressure lowering is associated with an increase in the photopic negative response (PhNR) amplitude in glaucoma and ocular hypertensive eyes. *Invest Ophthalmol Vis Sci* 2013; **54**: 1913-9.
6. Gandolfi SA, Cimino L, Sangermani C, Ungaro N, Mora P, Tardini MG. Improvement of spatial contrast sensitivity threshold after surgical reduction of intraocular pressure in unilateral high-tension glaucoma. *Invest Ophthalmol Vis Sci* 2005; **46**: 197-201.
7. Casson RJ, Han G, Ebnetter A, Chidlow G, Glihotra J, Newland H, Wood JP. Glucose-induced temporary visual recovery in primary open-angle glaucoma: a double-blind, randomized study. *Ophthalmology* 2014; **121**: 1203-11.
8. Viswanathan S, Frishman LJ, Robson JG, Walters JW. The photopic negative response of the flash electroretinogram in primary open angle glaucoma. *Invest Ophthalmol Vis Sci* 2001; **42**: 514-22.
9. Bui BV, Fortune B. Ganglion cell contributions to the rat full-field electroretinogram. *J Physiol* 2004; **555**: 153-73.
10. Colotto A, Falsini B, Salgarello T, Iarossi G, Galan ME, Scullica L. Photopic negative response of the human ERG: losses associated with glaucomatous damage. *Invest Ophthalmol Vis Sci* 2000; **41**: 2205-11.
11. Zhao D, Wong VHY, Nguyen CTO, Jobling AI, Fletcher EL, Vingrys AJ, Bui BV. Reversibility of Retinal Ganglion Cell Dysfunction From Chronic IOP Elevation. *Invest Ophthalmol Vis Sci* 2019; **60**: 3878-86.

- 491 12. Crowston JG, Kong YX, Trounce IA, Dang TM, Fahy ET, Bui BV, Morrison JC, Chrysostomou V. An
492 acute intraocular pressure challenge to assess retinal ganglion cell injury and recovery in the mouse.
493 *Exp Eye Res* 2015; **141**: 3-8.
- 494 13. Fry LE, Fahy E, Chrysostomou V, Hui F, Tang J, van Wijngaarden P, Petrou S, Crowston JG. The
495 coma in glaucoma: Retinal ganglion cell dysfunction and recovery. *Prog Retin Eye Res* 2018; **65**: 77-
496 92.
- 497 14. Kong YX, van Bergen N, Bui BV, Chrysostomou V, Vingrys AJ, Trounce IA, Crowston JG. Impact of
498 aging and diet restriction on retinal function during and after acute intraocular pressure injury.
499 *Neurobiol Aging* 2012; **33**: 1126 e15-25.
- 500 15. Chrysostomou V, Galic S, van Wijngaarden P, Trounce IA, Steinberg GR, Crowston JG. Exercise
501 reverses age-related vulnerability of the retina to injury by preventing complement-mediated synapse
502 elimination via a BDNF-dependent pathway. *Aging Cell* 2016.
- 503 16. Crowston JG, Fahy ET, Fry L, Trounce IA, van Wijngaarden P, Petrou S, Chrysostomou V. Targeting
504 retinal ganglion cell recovery. *Eye (Lond)* 2017; **31**: 196-8.
- 505 17. Tang J, Hui F, Hadoux X, Sarossy M, van Wijngaarden P, Coote M, Crowston JG. A Comparison of
506 the RETeval Sensor Strip and DTL Electrode for Recording the Photopic Negative Response. *Transl*
507 *Vis Sci Technol* 2018; **7**: 27.
- 508 18. Tang J, Hui F, Coote M, Crowston JG, Hadoux X. Baseline Detrending for the Photopic Negative
509 Response. *Transl Vis Sci Technol* 2018; **7**: 9.
- 510 19. Fivenson EM, Lautrup S, Sun N, Scheibye-Knudsen M, Stevnsner T, Nilsen H, Bohr VA, Fang EF.
511 Mitophagy in neurodegeneration and aging. *Neurochem Int* 2017.
- 512 20. Lee S, Sheck L, Crowston JG, Van Bergen NJ, O'Neill EC, O'Hare F, Kong YX, Chrysostomou V,
513 Vincent AL, Trounce IA. Impaired complex-I-linked respiration and ATP synthesis in primary open-
514 angle glaucoma patient lymphoblasts. *Invest Ophthalmol Vis Sci* 2012; **53**: 2431-7.
- 515 21. Osborne NN, del Olmo-Aguado S. Maintenance of retinal ganglion cell mitochondrial functions as a
516 neuroprotective strategy in glaucoma. *Curr Opin Pharmacol* 2013; **13**: 16-22.
- 517 22. van de Ven RA, Santos D, Haigis MC. Mitochondrial Sirtuins and Molecular Mechanisms of Aging.
518 *Trends Mol Med* 2017; **23**: 320-31.

- 519 23. Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, Redpath P, Migaud ME, Apte RS,
520 Uchida K, Yoshino J, Imai SI. Long-Term Administration of Nicotinamide Mononucleotide Mitigates
521 Age-Associated Physiological Decline in Mice. *Cell Metab* 2016; **24**: 795-806.
- 522 24. Srivastava S. Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related
523 disorders. *Clin Transl Med* 2016; **5**: 25.
- 524 25. Williams PA, Harder JM, John SWM. Glaucoma as a Metabolic Optic Neuropathy: Making the Case
525 for Nicotinamide Treatment in Glaucoma. *J Glaucoma* 2017; **26**: 1161-8.
- 526 26. Kouassi Nzoughe J, Chao de la Barca JM, Guehlouz K, Leruez S, Coulbault L, Allouche S, Bocca C,
527 Muller J, Amati-Bonneau P, Gohier P, Bonneau D, Simard G, Milea D, Lenaers G, Procaccio V,
528 Reynier P. Nicotinamide Deficiency in Primary Open-Angle Glaucoma. *Invest Ophthalmol Vis Sci*
529 2019; **60**: 2509-14.
- 530 27. Williams PA, Harder JM, Foxworth NE, Cochran KE, Philip VM, Porciatti V, Smithies O, John SW.
531 Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. *Science* 2017;
532 **355**: 756-60.
- 533 28. Chen AC, Martin AJ, Choy B, Fernandez-Penas P, Dalziel RA, McKenzie CA, Scolyer RA, Dhillon
534 HM, Vardy JL, Krickler A, St George G, Chinniah N, Halliday GM, Damian DL. A Phase 3
535 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. *N Engl J Med* 2015; **373**: 1618-
536 26.
- 537 29. Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, Gale EA, European
538 Nicotinamide Diabetes Intervention Trial G. Safety of high-dose nicotinamide: a review. *Diabetologia*
539 2000; **43**: 1337-45.
- 540 30. Johnson CA, Keltner JL, Cello KE, Edwards M, Kass MA, Gordon MO, Budenz DL, Gaasterland DE,
541 Werner E, Ocular Hypertension Study G. Baseline visual field characteristics in the ocular
542 hypertension treatment study. *Ophthalmology* 2002; **109**: 432-7.
- 543 31. Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study:
544 study design, methods, and baseline characteristics of enrolled patients. *Ophthalmology* 1999; **106**:
545 653-62.
- 546 32. Hui F, Tang J, Hadoux X, Coote M, Crowston JG. Optimizing a Portable ERG Device for Glaucoma
547 Clinic: The Effect of Interstimulus Frequency on the Photopic Negative Response. *Transl Vis Sci*
548 *Technol* 2018; **7**: 26.

- 549 33. Fulton AB, Hansen RM. Scotopic stimulus/response relations of the B-wave of the electroretinogram.
550 *Doc Ophthalmol* 1988; **68**: 293-304.
- 551 34. Binns AM, Mortlock KE, North RV. The relationship between stimulus intensity and response
552 amplitude for the photopic negative response of the flash electroretinogram. *Doc Ophthalmol* 2011;
553 **122**: 39-52.
- 554 35. Joshi NR, Ly E, Viswanathan S. Intensity response function of the photopic negative response (PhNR):
555 effect of age and test-retest reliability. *Doc Ophthalmol* 2017; **135**: 1-16.
- 556 36. Gardiner SK, Demirel S, Johnson CA, Swanson WH. Assessment of linear-scale indices for perimetry
557 in terms of progression in early glaucoma. *Vision Res* 2011; **51**: 1801-10.
- 558 37. Garway-Heath DF, Holder GE, Fitzke FW, Hitchings RA. Relationship between electrophysiological,
559 psychophysical, and anatomical measurements in glaucoma. *Invest Ophthalmol Vis Sci* 2002; **43**: 2213-
560 20.
- 561 38. Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on
562 evaluation of scientific publications. *Dtsch Arztebl Int* 2012; **109**: 276-81.
- 563 39. Sehi M, Grewal DS, Goodkin ML, Greenfield DS. Reversal of retinal ganglion cell dysfunction after
564 surgical reduction of intraocular pressure. *Ophthalmology* 2010; **117**: 2329-36.
- 565 40. Ventura LM, Porciatti V. Restoration of retinal ganglion cell function in early glaucoma after
566 intraocular pressure reduction: a pilot study. *Ophthalmology* 2005; **112**: 20-7.
- 567 41. Evans DW, Hosking SL, Gherghel D, Bartlett JD. Contrast sensitivity improves after brimonidine
568 therapy in primary open angle glaucoma: a case for neuroprotection. *Br J Ophthalmol* 2003; **87**: 1463-5.
- 569 42. Shibeb O, Chidlow G, Han G, Wood JP, Casson RJ. Effect of subconjunctival glucose on retinal
570 ganglion cell survival in experimental retinal ischaemia and contrast sensitivity in human glaucoma.
571 *Clin Exp Ophthalmol* 2016; **44**: 24-32.
- 572 43. Wright TM, Goharian I, Gardiner SK, Sehi M, Greenfield DS. Short-term enhancement of visual field
573 sensitivity in glaucomatous eyes following surgical intraocular pressure reduction. *Am J Ophthalmol*
574 2015; **159**: 378-85 e1.
- 575 44. Caprioli J, de Leon JM, Azarbod P, Chen A, Morales E, Nouri-Mahdavi K, Coleman A, Yu F, Afifi A.
576 Trabeculectomy Can Improve Long-Term Visual Function in Glaucoma. *Ophthalmology* 2016; **123**:
577 117-28.
- 578 45. Katsyuba E, Auwerx J. Modulating NAD⁺ metabolism, from bench to bedside. *EMBO J* 2017.

579 46. Williams PA, Harder JM, Cardozo BH, Foxworth NE, John SWM. Nicotinamide treatment robustly
580 protects from inherited mouse glaucoma. *Commun Integr Biol* 2018; **11**: e1356956.

581 47. Kamel K, Farrell M, O'Brien C. Mitochondrial dysfunction in ocular disease: Focus on glaucoma.
582 *Mitochondrion* 2017; **35**: 44-53.

583 48. Domanico D, Verboschi F, Altimari S, Zompatori L, Vingolo EM. Ocular Effects of Niacin: A Review
584 of the Literature. *Med Hypothesis Discov Innov Ophthalmol* 2015; **4**: 64-71.

585 49. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical
586 pharmacology. *Clinical pharmacology and therapeutics* 2007; **82**: 87-96.

587 50. Petley A, Macklin B, Renwick AG, Wilkin TJ. The pharmacokinetics of nicotinamide in humans and
588 rodents. *Diabetes* 1995; **44**: 152-5.

589